Drugs that contain Mitapivat Sulfate
1. Drug name - PYRUKYND
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8785450 | AGIOS PHARMS INC | Therapeutic compounds and compositions |
Feb, 2031
(8 years from now) | |
| US11254652 | AGIOS PHARMS INC | Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
Nov, 2038
(16 years from now) | |
| CN104817498A | AGIOS PHARMS INC | Therapeutic Compound And Composition |
Jun, 2030
(7 years from now) | |
| CN102481300B | AGIOS PHARMS INC | Therapeutic Compound And Composition |
Jun, 2030
(7 years from now) | |
| CN104817498B | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| CN102481300A | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| IN381684B | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| IN330578B | AGIOS PHARMS INC | Quinoline-8-Sulfonamide Compounds |
Jun, 2030
(7 years from now) | |
| IN201200471P1 | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| IN201918008568A | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| EP3241554B1 | AGIOS PHARMS INC | Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity |
Jun, 2030
(7 years from now) | |
| EP2448582A1 | AGIOS PHARMS INC | Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity |
Jun, 2030
(7 years from now) | |
| EP3241554A1 | AGIOS PHARMS INC | Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity |
Jun, 2030
(7 years from now) | |
| EP2448582A4 | AGIOS PHARMS INC | Therapeutic Compounds And Compositions |
Jun, 2030
(7 years from now) | |
| EP2448582B1 | AGIOS PHARMS INC | Quinoline-8-Sulfonamide Derivatives Having An Anticancer Activity |
Jun, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682080 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
| US9980961 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
| US10632114 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
May, 2032
(9 years from now) | |
| US9193701 | AGIOS PHARMS INC | Pyruvate kinase activators for use in therapy |
Oct, 2032
(10 years from now) | |
| US11234976 | AGIOS PHARMS INC | Methods of using pyruvate kinase activators |
Oct, 2038
(16 years from now) | |
Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency by administering a daily dose of 10mg to 100mg
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 50MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.